% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Baldus:49726,
      author       = {Baldus, O. and Waser, R.},
      title        = {{E}xperimental and numerical investigations of heat
                      transport and crystallization kinetics in laser-induced
                      modification of barium strontium titanate thin films},
      journal      = {Applied physics / A},
      volume       = {80},
      issn         = {0947-8396},
      address      = {Berlin},
      publisher    = {Springer},
      reportid     = {PreJuSER-49726},
      pages        = {1553},
      year         = {2005},
      note         = {Record converted from VDB: 12.11.2012},
      abstract     = {Venous thromboembolism is treated with unfractionated
                      heparin or low-molecular-weight heparin, followed by a
                      vitamin K antagonist. We investigated the potential use of
                      idraparinux, a long-acting inhibitor of activated factor X,
                      as a substitute for standard therapy.We conducted two
                      randomized, open-label noninferiority trials involving 2904
                      patients with deep-vein thrombosis and 2215 patients with
                      pulmonary embolism to compare the efficacy and safety of
                      idraparinux versus standard therapy. Patients received
                      either subcutaneous idraparinux (2.5 mg once weekly) or a
                      heparin followed by an adjusted-dose vitamin K antagonist
                      for either 3 or 6 months. The primary efficacy outcome was
                      the 3-month incidence of symptomatic recurrent venous
                      thromboembolism (nonfatal or fatal).In the study of patients
                      with deep venous thrombosis, the incidence of recurrence at
                      day 92 was $2.9\%$ in the idraparinux group as compared with
                      $3.0\%$ in the standard-therapy group (odds ratio, 0.98;
                      $95\%$ confidence interval [CI], 0.63 to 1.50), a result
                      that satisfied the prespecified noninferiority requirement.
                      At 6 months, the hazard ratio for idraparinux was 1.01. The
                      rates of clinically relevant bleeding at day 92 were $4.5\%$
                      in the idraparinux group and $7.0\%$ in the standard-therapy
                      group (P=0.004). At 6 months, bleeding rates were similar.
                      In the study of patients with pulmonary embolism, the
                      incidence of recurrence at day 92 was $3.4\%$ in the
                      idraparinux group and $1.6\%$ in the standard-therapy group
                      (odds ratio, 2.14; $95\%$ CI, 1.21 to 3.78), a finding that
                      did not meet the noninferiority requirement.In patients with
                      deep venous thrombosis, once-weekly subcutaneous idraparinux
                      for 3 or 6 months had an efficacy similar to that of heparin
                      plus a vitamin K antagonist. However, in patients with
                      pulmonary embolism, idraparinux was less efficacious than
                      standard therapy. (ClinicalTrials.gov numbers, NCT00067093
                      [ClinicalTrials.gov] and NCT00062803
                      [ClinicalTrials.gov].).},
      keywords     = {Anticoagulants: adverse effects / Anticoagulants:
                      therapeutic use / Female / Follow-Up Studies / Hemorrhage:
                      chemically induced / Heparin: adverse effects / Heparin:
                      therapeutic use / Humans / Incidence / Male / Middle Aged /
                      Oligosaccharides: adverse effects / Oligosaccharides:
                      therapeutic use / Pulmonary Embolism: drug therapy /
                      Pulmonary Embolism: mortality / Recurrence / Treatment
                      Outcome / Venous Thrombosis: drug therapy / Venous
                      Thrombosis: mortality / Vitamin K: antagonists $\&$
                      inhibitors / Anticoagulants (NLM Chemicals) /
                      Oligosaccharides (NLM Chemicals) / idraparinux (NLM
                      Chemicals) / Vitamin K (NLM Chemicals) / Heparin (NLM
                      Chemicals) / J (WoSType)},
      cin          = {IFF-IEM / CNI},
      ddc          = {530},
      cid          = {I:(DE-Juel1)VDB321 / I:(DE-Juel1)VDB381},
      pnm          = {Materialien, Prozesse und Bauelemente für die Mikro- und
                      Nanoelektronik},
      pid          = {G:(DE-Juel1)FUEK252},
      shelfmark    = {Materials Science, Multidisciplinary / Physics, Applied},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:17855670},
      UT           = {WOS:000227908400030},
      doi          = {10.1007/s00339-004-2904-7},
      url          = {https://juser.fz-juelich.de/record/49726},
}